Denali Therapeutics Inc. (DNLI): who owns it and who trades it
As of Nov 16, 2026, DNLI insiders reported 7 open-market sales worth $1.3M and no purchases in the last 12 months, with 25% of the sale value made under pre-set 10b5-1 plans. The largest seller was Ryan J. Watts (CEO), with $581K. 6 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Denali Therapeutics
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns DNLI
293 funds and institutions reported DNLI shares worth $4.2B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is T. Rowe Price Investment Management, Inc. with 10.2%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 16.18M | 10.19% | $416M | +90% |
| BlackRock, Inc. | 14.03M | 8.84% | $361M | +8% |
| Baillie Gifford & Co | 11.96M | 7.54% | $308M | -1% |
| State Street Corp | 7.05M | 4.44% | $181M | +12% |
| Temasek Holdings (Private) Ltd | 7.01M | 4.42% | $180M | No change |
| Vanguard Portfolio Management LLC | 6.48M | 4.08% | $167M | +6% |
| Vanguard Capital Management LLC | 6.28M | 3.95% | $161M | +2% |
| FMR LLC (Fidelity) | 4.54M | 2.86% | $117M | -1% |
| Goldman Sachs Group Inc | 4.16M | 2.62% | $107M | -6% |
| Geode Capital Management, LLC | 3.97M | 2.50% | $102M | +7% |
| California State Teachers Retirement System | 3.91M | 2.46% | $152M | +2306% |
| Holocene Advisors, LP | 3.91M | 2.46% | $100M | +22% |
| Baker Bros. Advisors LP | 3.73M | 2.35% | $96M | +0% |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 3.16M | 1.99% | $81.3M | -29% |
| T. Rowe Price Associates | 3.14M | 1.98% | $80.7M | +27% |
| UBS Group AG | 3.12M | 1.97% | $80.3M | +21% |
| Alliancebernstein L.P. | 2.98M | 1.88% | $57.3M | +3% |
| Dimensional Fund Advisors LP | 2.86M | 1.80% | $73.6M | +6% |
| Norges Bank | 2.82M | 1.78% | $72.7M | – |
| Pictet Asset Management Holding SA | 2.79M | 1.76% | $71.9M | +9% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, DNLI insiders reported $0 of open-market purchases and $1.3M of sales. 25% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 4, 2026 | Peter Scott Chin | Chief Medical Officer | Sale | 1,654 | $22.29 | $36.9K | Form 4 |
| Sep 2, 2026 | Nancy Thornberry | Director | Sale plan | 10,824 | $22.85 | $247K | Form 4 |
| Sep 2, 2026 | Nancy Thornberry | Director | Sale plan | 615 | $23.74 | $14.6K | Form 4 |
| Sep 1, 2026 | Alexander O. Schuth | COFO and Secretary | Sale plan | 2,768 | $23.44 | $64.9K | Form 4 |
| Aug 11, 2026 | Alexander O. Schuth | COFO and Secretary | Sale | 2,857 | $25.07 | $71.6K | Form 4 |
| Jan 6, 2026 | Ryan J. Watts | CEO | Sale | 35,198 | $16.50 | $581K | Form 4 |
| Jan 6, 2026 | Alexander O. Schuth | COFO and Secretary | Sale | 17,218 | $16.50 | $284K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Ryan J. Watts | President and CEO, Director | – | $581K | Jan 6, 2026 |
| Alexander O. Schuth | COFO and Secretary | – | $421K | Sep 1, 2026 |
| Nancy Thornberry | Director | – | $262K | Sep 2, 2026 |
| Peter Scott Chin | Chief Medical Officer | – | $36.9K | Sep 4, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
DNLI short interest
Moderate short interest. 9.2% of DNLI shares are sold short: about 1 share in 11. Over the last 12 reports the number of shares short went up 5%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 14.69M DNLI shares were sold short, 9.2% of the shares outstanding, down 5.0% from the report before. At the average daily volume of 1.48M shares, buying them all back would take about 9.9 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 14.69M | 9.17% | -5% | 1.48M | 9.9 |
| Oct 15, 2026 | 15.48M | 9.68% | +0% | 1.92M | 8.1 |
| Sep 30, 2026 | 15.46M | 9.67% | -10% | 2.02M | 7.6 |
| Sep 15, 2026 | 17.14M | 10.72% | +3% | 1.43M | 12.0 |
| Aug 31, 2026 | 16.64M | 10.41% | -7% | 951,216 | 17.5 |
| Aug 14, 2026 | 17.96M | 11.24% | +3% | 1.45M | 12.4 |
| Jul 31, 2026 | 17.43M | 10.91% | +9% | 1.44M | 12.1 |
| Jul 15, 2026 | 16.04M | 10.10% | +1% | 1.91M | 8.4 |
| Jun 30, 2026 | 15.95M | 10.05% | +4% | 2.30M | 7.0 |
| Jun 15, 2026 | 15.41M | 9.71% | +3% | 1.83M | 8.4 |
| May 29, 2026 | 14.99M | 9.45% | +7% | 1.87M | 8.0 |
| May 15, 2026 | 14.03M | 8.84% | -5% | 1.87M | 7.5 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Denali Therapeutics company events
Denali Therapeutics filed 15 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 3, 2026.
- Nov 3, 2026ResultsReleased financial results. Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- Jul 28, 2026DealDenali Therapeutics Inc. completed the previously disclosed sale of its Rare Pediatric Disease Priority Review Voucher to a large pharmaceutical company. Filing
- Jun 18, 2026AgreementDenali Therapeutics Inc. entered into an asset purchase agreement, pursuant to which the Company agreed to sell its Rare Pediatric Disease Priority Review Voucher. Filing
- Jun 4, 2026VoteReported shareholder vote results. Filing
- May 22, 2026AnnouncementShared information with investors. Filing
- May 7, 2026ResultsReleased financial results. Filing
- Apr 3, 2026AgreementEnded an important agreement. Filing
- Mar 31, 2026DebtTook on new debt. Filing
- Mar 25, 2026AnnouncementShared information with investors. Filing
- Feb 26, 2026ResultsReleased financial results. Filing
- Jan 6, 2026AnnouncementShared information with investors. Filing
- Dec 10, 2025AgreementDenali Therapeutics Inc. entered into an underwriting agreement with Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC as representatives of the several underwriters named therein, relating to the public offering of 9,142,857 shares of the Company’s common stock, par… Filing
- Dec 4, 2025AnnouncementDenali provided the following key updates on programs across its development pipeline at its 2025 Investor Day. Filing
- Dec 4, 2025AgreementDenali Therapeutics Inc. entered into a synthetic royalty funding agreement with Royalty Pharma plc. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Denali Therapeutics financials
Famous investors that hold DNLI
6 of the 50 well-known investors we track reported holding DNLI in their latest 13F filing. The largest position is Ken Fisher's, worth $50.9M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Fisher · Fisher Asset Management | Q3 2026 | 2.46M | $50.9M | 0.0% | +2% |
| Israel Englander · Millennium Management | Q3 2026 | 749,575 | $15.5M | 0.0% | -33% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 595,777 | $12.3M | 0.0% | +790% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 218,700 | $4.5M | 0.0% | New |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 63,692 | $1.3M | 0.0% | +55% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 61,189 | $1.3M | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named DNLI in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | T. Rowe Price Investment Management, Inc. | 13G/A | 12.3% |
| Nov 16, 2026 | T. Rowe Price Investment Management, Inc. | 13G/A | 12.3% |
Questions about Denali Therapeutics Inc. (DNLI) stock
Who owns the most DNLI stock?
The largest reported owner of Denali Therapeutics Inc. (DNLI) is T. Rowe Price Investment Management, Inc., with 10.2% of the company. In total, 293 funds and institutions reported holding DNLI at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are DNLI insiders buying or selling?
In the last 12 months, DNLI insiders reported no open-market purchases and 7 sales worth $1.3M. The latest trade was on Sep 4, 2026. See every trade.
What is the short interest in DNLI?
As of Oct 30, 2026, 14.69M DNLI shares were sold short, 9.2% of the shares outstanding, down 5.0% from the report before. At the average daily volume of 1.48M shares, buying them all back would take about 9.9 trading days (days to cover). See the history.
Which famous investors hold DNLI?
6 of the 50 well-known investors we track reported DNLI in their latest 13F filing, including Ken Fisher, Israel Englander, Ken Griffin. The largest position is worth $50.9M. See all holders.
Executive pay
Denali Therapeutics's chief executive was paid a total of $4.8M for the year ended Dec 31, 2025, down 28% from $6.6M the year before. In the last 12 months, Denali Therapeutics's executives and directors bought no stock on the open market and sold $1.3M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.